目的：探讨瑞舒伐他汀对颈动脉粥样硬化斑块的影响。方法：选取2014年9月—2015年3月滨州市第二人民医院神经内二科脑梗死住院患者中经超声证实存在颈动脉粥样硬化斑块的患者135例，以随机数字表法分为治疗组和对照组。治疗组70例患者给予瑞舒伐他汀10 mg、1日1次、口服，对照组65患者给予辛伐他汀20 mg、1日1次、口服，比较治疗前和治疗12个月末2组患者最大颈动脉内膜－中层厚度及相应斑块面积变化情况。结果：治疗12个月末，治疗组患者最大颈动脉内膜－中层厚度[（2．07±0．86） mm vs．（1．19±0．74） mm]、相应斑块面积[（20．45±1．91） mm2 vs．（11．23±1．69） mm2]，均较治疗前明显改善，且明显优于治疗后对照组患者最大颈动脉内膜－中层厚度[（1．59±0．77） mm]、相应斑块面积[（15．24±1．72） mm2]，差异均有统计学意义（ P＜0．05）。结论：脑梗死患者服用瑞舒伐他汀可逆转颈动脉粥样硬化斑块。%OBJECTIVE:To probe into the effects of rosuvastatin on the carotid atheromatous plaque.METHODS:135 patients with carotid atheromatous plaque admitted into department of neurology in Binzhou the Second People’s Hospital from Sept.2014 to Mar.2015 were selected to be divided into treatment group and control group via the random number table.70 patients in treatment group were given rosuvastatin 10 mg, once a day, while 65 patients in control group were given simvastatin 20 mg, once a day.Changes of the thickest carotid intima-media thickness and the plaque size before and after 12 months of treatment were compared between two groups.RESULTS: After 12 months of treatment, the thickest carotid intima-media thickness and the plaque size of treatment group were respectively [(2.07 ±0.86) mm vs.(1.19 ±0.74) mm] and [(20.45 ±1.91) mm2 vs.(11.23 ±1.69) mm2], which were significantly improved compared with before treatment, and remarkable better than those of control group [(1.59 ±0.77) mm]、[(15.24 ±1.72) mm2], with statistically significant difference(P<0.05).CONCLUSIONS:Rosuvastatin in treatment of patients with carotid atheromatous plaque can result in significant regression of carotid atheromatous plaque.
展开▼
